Endocrine Abstracts

Purpose: We aim at prospectively comparing the detection rate of GLP1-R PET/CT vs GLP1-R SPECT/CT vs standardized contrast enhanced 3T-MRI in patients with suspected insulinoma.Methods: 40 patients with neuroglycopenic symptoms due to endogenous hyperinsulinemic hypoglycemia were enrolled.3T-MRI was performed. Afterwards patients received SPECT/CT after injection of 111In-DOTA-exendin-4 and PET/CT after injection of <sup...

Background: Biochemical biomarker DT is used clinically for prognosis prediction in several solid malignancies. The aim of the current analysis was to determine whether biomarker DT has any prognostic utility in patients with NETs.Methods: Patients with NETs (n=184) were enrolled in a prospective study with comprehensive biochemical analysis. The current analysis included subjects with increasing 5-HIAA levels in at least two consecutive measure...

Background: Pasireotide is a multireceptor-targeted somatostatin analogue that predominantly binds to somatostatin receptor subtype 5 (SSTR5) and provides sustained control of urinary free cortisol (UFC) levels in some patients with Cushing’s disease (CD). Cabergoline is a dopamine D2 receptor agonist with efficacy in some patients with CD. Most corticotropinomas co-express SSTR5 and D2, providing rationale for combination treatment with pasireotide and cabergoline. Resul...

Introduction: Skeletal complications of acromegaly are among its most persistent and invalidating impacts. Dual-X-ray absorptiometry (DXA) alone might be insufficient or even misleading for bone health assessment in acromegaly.Patients and methods: Patients with acromegaly (N=170) were classified as active (N=104), operatively cured (N=34) or medically controlled (N=32). 57 males and 113 females were included, 52.8 (22...

Pituitary dysfunction can be a consequence of cranial radiotherapy. It usually occurs years after the treatment. However little is known on risk factors for pituitary dysfunction. The object of this study was to evaluate radiation induced pituitary toxicity of proton beam therapy in a cohort of adult chondrosarcoma patients.The files of 113 patients were reviewed. Mean age at the beginning of radiotherapy was 43 years old (18–76). Mean dose delivere...

Background: Long-term safety data (1998 to mid-2016) are reported for adult patients with GHD treated with GH (Norditropin® (somatropin), Novo Nordisk) as prescribed by treating physicians in the real-life clinical setting and enrolled in NordiNet® International Outcome Study (IOS) (NCT00960128), a non-interventional, multicentre study.Objective and hypotheses: To describe and report safety data and incidence rates (IRs) (...

Background: In PRIMARYS, lanreotide Autogel (LAN) 120 mg/28 days reduced tumour volume (TV), and GH/IGF-1 levels in patients with GH-secreting macroadenomas. In post-hoc analyses, we investigated predictive factors for treatment responses.Methods: PRIMARYS, a 48-week, international, open-label study, involved 90 treatment-naïve patients with GH-secreting macroadenomas receiving LAN. Factors predictive for hormonal control (HC; GH ≤2.5...

Introduction: Pegvisomant (PEGV) is approved for the treatment of acromegaly since 2003. This is the second interim analysis of data from ACROSTUDY, with the majority of patients treated for at least five years (yrs).Methods/design: ACROSTUDY is an international, open-label, prospective, non-interventional, post-marketing surveillance study monitoring the long-term safety and efficacy of PEGV. Patients were enrolled in the study on an ongoing basis.<...

Background: Hyperprolactinemia is often seen in women of reproductive age (20–35 years), most often due to microprolactinoma. However, prolactinomas do occur in older women.Objective: To analyze clinical features of hyperprolactinemia in women >40 yearsMaterial and methods: Clinical and biochemical data of 185 women with pathological hyperprolactinemia were analyzed.Results: Seventy (37.8%) patients ...

We present a case of a patient with a locally invasive, serotonin- and ACTH-reactive tumour in the sellar region, filling the sphenoid sinus and expanding into the epipharynx. Clinical examination completed by 68-Gallium-DOTA-TOC PET revealed tracer uptake in the sellar tumour as well as in a 7 mm lesion in the pancreatic tail. A differential diagnosis between silent corticotroph adenoma and another primary or secondary neuroendocrine tumour (NET) with ACTH-expression was diff...

Introduction: Germline aryl hydrocarbon receptor-interacting protein (AIP) mutations are responsible for 15–30% of familial isolated pituitary adenomas (FIPA). We report a 4-generation FIPA kindred with a heterozygous AIP gene deletion in exon 2, highlighting the benefits of genetic screening and management challenges in affected subjects and asymptomatic carriers.Patients: A 45y woman died of a spinal ependymoma (obligate carrier)...

GH suppression during OGTT is the gold-standard test in diagnosis and monitoring of acromegaly. However, discrepancies between GH nadir and IGF-I have been described and have triggered search for factors modifying the extent of GH suppression. Cut-offs at 1.0 or 0.4 ng/ml are currently recommended with modern, highly sensitive GH assays. To establish assay specific GH nadir cutoffs for the 22kD GH specific IDS-iSYS assay, we examined 381 subjects (319 females, 62 males) with n...